Etanercept Biosimilar – Anti-TNF mAb – Research Grade

Reference:
Product nameEtanercept Biosimilar - Anti-TNF mAb - Research Grade
SourceDrugBank DB00005
SpeciesHuman
Molecular weight51kDa
Purity>85%
BufferPBS pH7.5
Delivery conditionBlue ice (+4°C)
Delivery lead time in business days3-5 days if in stock; 3-5 weeks if production needed
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
Aliases /SynonymsEtanercept,Etanercept,TNF,anti-TNF
ReferencePX-TA1015
NoteFor research use only. Not suitable for human use.
IsotypeIgG1-Fc
ClonalityMonoclonal Antibody

Description of Etanercept Biosimilar - Anti-TNF mAb - Research Grade

General information about Etanercept

Etanercept is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the “master regulator” of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha. Etanercept is a fusion protein produced by recombinant DNA. It fuses the TNF receptor to the constant end of the IgG1 antibody. First, the developers isolated the DNA sequence that codes the human gene for soluble TNF receptor 2, which is a receptor that binds to tumor necrosis factor-alpha. Second, they isolated the DNA sequence that codes the human gene for the Fc end of immunoglobulin G1 (IgG1). Third, they linked the DNA for TNF receptor 2 to the DNA for IgG1 Fc. Finally, they expressed the linked DNA to produce a protein that links the protein for TNF receptor 2 to the protein for IgG1 Fc. It is a large molecule, with a molecular weight of 150 kDa, that binds to TNF alpha and decreases its role in disorders involving excess inflammation in humans and other animals, including autoimmune diseases such as ankylosing spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and, potentially, in a variety of other disorders mediated by excess TNFalpha. This product is for research use only.

Etanercept Biosimilar - Anti-TNF mAb binds to TNFa / TNF-alpha, N-His, recombinant protein in indirect ELISA Assay

Immobilized TNFa / TNF-alpha, N-His, recombinant protein (cat. No.PX-P5961) at 0.5µg/mL (100µL/well) can bind to Etanercept Biosimilar - Anti-TNF mAb (cat. No.PX-TA1015) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Etanercept Biosimilar – Anti-TNF mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Related products

CD120a Recombinant Protein
Antigen

CD120a Recombinant Protein

PX-P4100 500$
CD257 Recombinant Protein
Antigen

CD257 Recombinant Protein

PX-P4112 500$
CD40 ligand(CD40LG)
Antigen

CD40 ligand(CD40LG)

PX-P4855 250$
CD95 Recombinant Protein
Antigen

CD95 Recombinant Protein

PX-P4095 500$
Human CD137–TNFRSF9-4–1BB recombinant protein
Antigen

Human CD137–TNFRSF9-4–1BB recombinant protein

PX-P4059 250$
Human CD270,TNFRSF14,HVEM recombinant protein
Antigen

Human CD270,TNFRSF14,HVEM recombinant protein

PX-P4039 250$
Anti-Etanercept Polyclonal Antibody
Polyclonal Antibody

Anti-Etanercept Polyclonal Antibody

PTX18867 774$

Contact us

Send us a message from the form below







    Cart (0 Items)

    Your cart is currently empty.

    View Products